7.1 Follow-up of multiple myeloma in response

Routine follow-up studies include, on completion of induction treatment and at least every 3 months, serum chemistry panel, complete blood count with differential, serum monoclonal Ig evaluation by nephelometry or electrophoresis and in case of BJ proteinuria, 24-hours urine protein electrophoresis.
Skeletal X-ray survey should be obtained at least annually, and in case of new bone pain. Bone marrow aspiration is recommended in case of significant abnormality in blood counts, increase of serum or urine monoclonal component or in case of new symptoms. The value of b2 microglobulin for following the course of myeloma has not been clearly demonstrated.

7.2 Follow-up of MGUS

No clear risk factors for progression to malignant disease have been identified so far, and periodic clinical and laboratory follow-up is recommended. If the M component is <2g/dl, follow up should be every 6 months for the first year and in case of no progression yearly. In case the M component is> 2g/dL or in case of any therafter increse >0.5 g/dL, patients should be rececked at 3-4 motnhs interval for the first year, and thereafter every 6-12 months in case of no further increase.

© European School of Oncology, 1996

Questions, requests, comments and messages should be sent to:
START secretariat, ESO, via Venezian 18, I-20133 Milano, Italy;
tel. no.: +39 2 2665033; fax no.: +39 2 2664662; e-mail: start@icil64.cilea.it